Exodus Point Capital Management, LP Otonomy, Inc. Transaction History

Exodus Point Capital Management, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 19, 2022	SELL	$1.72 - $2.51 $25,571 - $37,316	-14,867 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$1.72 - $2.47 $25,571 - $36,721	14,867 New	14,867 $36,000
Q4 2021 Feb 11, 2022	SELL	$1.69 - $2.31 $20,107 - $27,484	-11,898 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$1.22 - $2.2 $14,515 - $26,175	11,898 New	11,898 $23,000
Q2 2021 Aug 16, 2021	SELL	$2.06 - $2.67 $139,740 - $181,119	-67,835 Closed	0 $0

Q1 2021 May 17, 2021	SELL	$2.49 - $6.23 $691,141 - $1.73 Million	-277,567 Reduced 80.36%	67,835 $173,000
Q4 2020 Feb 16, 2021	BUY	$3.48 - $6.47 $1.2 Million - $2.23 Million	345,402 New	345,402 $2.24 Million

Ticker OTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,990,400
Description
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.